SLC7A6
Basic information
Region (hg38): 16:68264516-68301823
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC7A6 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 4 | |||||
missense | 18 | 22 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 19 | 5 | 3 |
Variants in SLC7A6
This is a list of pathogenic ClinVar variants found in the SLC7A6 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-68274758-C-T | not specified | Uncertain significance (Aug 04, 2022) | ||
16-68274771-T-C | SLC7A6-related disorder | Likely benign (Apr 09, 2019) | ||
16-68274804-A-T | SLC7A6-related disorder | Benign (Nov 11, 2019) | ||
16-68274972-T-G | not specified | Uncertain significance (Dec 01, 2022) | ||
16-68275155-C-T | SLC7A6-related disorder | Likely benign (Jun 19, 2019) | ||
16-68275192-T-C | not specified | Uncertain significance (Nov 28, 2023) | ||
16-68275226-G-A | not specified | Uncertain significance (May 17, 2023) | ||
16-68287803-C-T | not specified | Uncertain significance (Dec 04, 2021) | ||
16-68287814-G-A | not specified | Uncertain significance (Jun 22, 2021) | ||
16-68287833-T-C | not specified | Uncertain significance (Oct 22, 2021) | ||
16-68290419-G-A | not specified | Uncertain significance (Sep 16, 2021) | ||
16-68290429-G-A | not specified | Uncertain significance (Oct 26, 2022) | ||
16-68291300-T-A | Benign (Apr 16, 2018) | |||
16-68291575-G-A | SLC7A6-related disorder | Likely benign (Jun 18, 2019) | ||
16-68291598-T-C | not specified | Uncertain significance (May 11, 2022) | ||
16-68294740-C-T | not specified | Uncertain significance (Sep 09, 2021) | ||
16-68294748-C-A | not specified | Uncertain significance (Apr 09, 2024) | ||
16-68294787-G-C | not specified | Uncertain significance (Dec 20, 2022) | ||
16-68296374-C-T | not specified | Uncertain significance (Jun 11, 2024) | ||
16-68296494-A-G | Likely benign (Apr 10, 2018) | |||
16-68296499-C-T | not specified | Uncertain significance (Jan 12, 2024) | ||
16-68296659-A-G | not specified | Uncertain significance (Feb 07, 2023) | ||
16-68296727-T-C | Benign (Apr 16, 2018) | |||
16-68296780-C-T | not specified | Uncertain significance (Feb 22, 2023) | ||
16-68296805-T-C | not specified | Uncertain significance (Feb 23, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SLC7A6 | protein_coding | protein_coding | ENST00000566454 | 9 | 37290 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00973 | 0.988 | 125672 | 0 | 76 | 125748 | 0.000302 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.34 | 229 | 294 | 0.780 | 0.0000167 | 3334 |
Missense in Polyphen | 69 | 113.45 | 0.60821 | 1324 | ||
Synonymous | -0.898 | 134 | 121 | 1.10 | 0.00000743 | 1093 |
Loss of Function | 2.70 | 7 | 20.1 | 0.349 | 8.63e-7 | 238 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000174 | 0.000174 |
Ashkenazi Jewish | 0.00338 | 0.00338 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000211 | 0.000211 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000131 | 0.000131 |
Other | 0.000978 | 0.000978 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the sodium-independent uptake of dibasic amino acids and sodium-dependent uptake of some neutral amino acids. Requires coexpression with SLC3A2/4F2hc to mediate the uptake of arginine, leucine and glutamine. Also acts as an arginine/glutamine exchanger, following an antiport mechanism for amino acid transport, influencing arginine release in exchange for extracellular amino acids. Plays a role in nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-arginine. Involved in the transport of L-arginine in monocytes. Reduces uptake of ornithine in retinal pigment epithelial (RPE) cells. {ECO:0000269|PubMed:10903140, ECO:0000269|PubMed:11311135, ECO:0000269|PubMed:14603368, ECO:0000269|PubMed:15280038, ECO:0000269|PubMed:16785209, ECO:0000269|PubMed:17197568, ECO:0000269|PubMed:17329401, ECO:0000269|PubMed:9829974}.;
- Pathway
- Polythiazide Action Pathway;Methyclothiazide Action Pathway;Bumetanide Action Pathway;Spironolactone Action Pathway;Eplerenone Action Pathway;Triamterene Action Pathway;Amiloride Action Pathway;Ethacrynic Acid Action Pathway;Quinethazone Action Pathway;Bendroflumethiazide Action Pathway;Chlorthalidone Action Pathway;Trichlormethiazide Action Pathway;Iminoglycinuria;Lysinuric Protein Intolerance;Blue diaper syndrome;Lysinuric protein intolerance (LPI);Cystinuria;Indapamide Action Pathway;Furosemide Action Pathway;Torsemide Action Pathway;Hartnup Disorder;Glucose Transporter Defect (SGLT2);Kidney Function;Glucose Transporter Defect (SGLT2);Metolazone Action Pathway;Hydrochlorothiazide Action Pathway;Cyclothiazide Action Pathway;Hydroflumethiazide Action Pathway;Chlorothiazide Action Pathway;miR-targeted genes in leukocytes - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Amino acid transport across the plasma membrane;Amino acid and oligopeptide SLC transporters;Fibroblast growth factor-1;Transport of inorganic cations/anions and amino acids/oligopeptides;SLC-mediated transmembrane transport;Transport of small molecules;Cell surface interactions at the vascular wall;Hemostasis;Basigin interactions;Glycine, serine, alanine and threonine metabolism
(Consensus)
Recessive Scores
- pRec
- 0.102
Intolerance Scores
- loftool
- 0.184
- rvis_EVS
- 0.02
- rvis_percentile_EVS
- 55.61
Haploinsufficiency Scores
- pHI
- 0.145
- hipred
- Y
- hipred_score
- 0.541
- ghis
- 0.466
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.508
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Slc7a6
- Phenotype
Gene ontology
- Biological process
- amino acid transmembrane transport;cellular amino acid metabolic process;leukocyte migration;protein-containing complex assembly;L-alpha-amino acid transmembrane transport
- Cellular component
- plasma membrane;integral component of plasma membrane;basolateral plasma membrane;intracellular membrane-bounded organelle
- Molecular function
- amino acid transmembrane transporter activity;L-amino acid transmembrane transporter activity;antiporter activity